These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19673711)

  • 1. Safety and efficacy of bivalirudin in high-risk patients admitted through the emergency department.
    Miller CD; Blomkalns AL; Gersh BJ; Pollack CV; Brogan GX; Diercks DB; Peacock WF; Stone GW; Hollander JE; Manoukian SV; Hoekstra JW;
    Acad Emerg Med; 2009 Aug; 16(8):717-25. PubMed ID: 19673711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Feit F; Manoukian SV; Ebrahimi R; Pollack CV; Ohman EM; Attubato MJ; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Apr; 51(17):1645-52. PubMed ID: 18436116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
    Huang X; Chen S; Redfors B; Zhang Y; Souza CF; Mehran R; Bansilal S; Kirtane AJ; Brener SJ; Feite F; Dangas GD; Ben-Yehuda O; Stone GW
    Coron Artery Dis; 2020 Jan; 31(1):59-65. PubMed ID: 31809479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
    J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).
    Lansky AJ; Mehran R; Cristea E; Parise H; Feit F; Ohman EM; White HD; Alexander KP; Bertrand ME; Desmet W; Hamon M; Stone GW
    Am J Cardiol; 2009 May; 103(9):1196-203. PubMed ID: 19406258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
    Mehran R; Nikolsky E; Lansky AJ; Kirtane AJ; Kim YH; Feit F; Manoukian S; Moses JW; Ebrahimi R; Ohman EM; White HD; Pocock SJ; Dangas GD; Stone GW
    JACC Cardiovasc Interv; 2009 Aug; 2(8):748-57. PubMed ID: 19695543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
    Kumar D; Dangas G; Mehran R; Kirtane A; Bertrand M; Ebrahimi R; Guagliumi G; Brar S; Fahy M; Heller E; Moses J; Stone G
    Am J Cardiol; 2010 Oct; 106(7):941-5. PubMed ID: 20854954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy.
    Goto K; Lansky AJ; Fahy M; Cristea E; Feit F; Ohman EM; White HD; Alexander KP; Bertrand ME; Desmet W; Hamon M; Mehran R; Stone GW
    Circulation; 2010 Feb; 121(7):853-62. PubMed ID: 20142447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.
    Navarese EP; Schulze V; Andreotti F; Kowalewski M; Kołodziejczak M; Kandzari DE; Rassaf T; Gorny B; Brockmeyer M; Meyer C; Berti S; Kubica J; Kelm M; Valgimigli M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):201-213. PubMed ID: 25616926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
    JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
    Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
    Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    Feldman DN; Wong SC; Bergman G; Minutello RM
    J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Nikolsky E; McLaurin BT; Cox DA; Manoukian SV; Xu K; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2012 Sep; 5(9):919-26. PubMed ID: 22995879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
    Maroo A; Lincoff AM
    Semin Thromb Hemost; 2004 Jun; 30(3):329-36. PubMed ID: 15282655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.